It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We documented dramatic responses to infliximab in 4 tuberculous meningitis cases with severe paradoxical reactions after effective antibacterial treatment, despite high-dose steroids. In every instance, infliximab was used as a last resort after all other options were exhausted, resulting in delayed initiation that may have adversely affected patient outcomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI), University of Sydney, Sydney, Australia
2 Department of Infectious Diseases and Microbiology, Concord Repatriation General Hospital, Sydney, Australia
3 Department of Microbiology and Infectious Diseases, Royal North Shore Hospital, Sydney, Australia
4 Department of Infectious Diseases and Microbiology, Flinders Medical Centre and Flinders University, Adelaide, Australia
5 The Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI), University of Sydney, Sydney, Australia; Centre for Infectious Diseases and Microbiology Infectious Diseases and Microbiology (CIDM), Westmead Hospital, Sydney, Australia; ICPMR Westmead Hospital, NSW Health Pathology, Sydney, Australia
6 The Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI), University of Sydney, Sydney, Australia; ICPMR Westmead Hospital, NSW Health Pathology, Sydney, Australia
7 Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia
8 Department of Clinical Immunology/Allergy, Concord Repatriation General Hospital, Sydney, Australia